“The majority of COPD exacerbations are due to bacterial or viral infections; some are recognised to be due to environmental pollution and in approximately one-third of cases the aetiology remains unclear,” Prof. Surya P. Bhatt (Birmingham School of Medicine, AL, USA) explained [1]. As the current definition of an acute exacerbation of COPD (AECOPD) is based on acute symptom worsening without mentioning aetiologies, 4 clusters of possible phenotypes were distinguished: bacteria-predominant, eosinophil-predominant, virus-predominant, and pauci-inflammatory [2]. All might require different treatment strategies, and this could play a special role in the pauci-inflammatory group constituting about 20% of AECOPD with no clear identifiable cause [1].
Meta-analyses have established an association between COPD and cardiac disease, especially coronary artery disease and cardiac arrhythmias [1]. It has been hypothesised that AECOPD could be linked to unrecognised arrhythmias, and a small study indeed found that p-wave dispersion, a surrogate for atrial arrhythmia, is greater during exacerbation than during the stable phase, hence possibly predating AECOPD [3]. Furthermore, diastolic dysfunction is a point of discussion: Prof. Bhatt presented unpublished data that found a 3-fold increase of severe exacerbations in patients with diastolic dysfunction and evidence of subclinical pulmonary oedema [1].
“Another comorbidity frequently noted in those with COPD is psychological distress in the form of anxiety or depression, which is present in up to 55% of individuals with COPD,” informed Prof. Bhatt. Depression carries a higher risk for severe exacerbations as well as short- and long-term readmission to hospital [4,5]. However, anxiety is linked to an amplified risk for mild-to-moderate exacerbations, which could be due to augmented awareness of physical symptoms in anxiety patients [1,4].
Gastroesophageal reflux disease: a novel risk factor for AECOPD
An entirely different condition increasing the likelihood of AECOPD is gastroesophageal reflux disease (GERD). A recent meta-analysis identified that the presence of GERD augmented the odds for exacerbated COPD by 5-fold (OR 5.37; 95% CI 2.71–10.64) [6].
Also, vocal cord dysfunction (VCD) and expiratory central airway collapse were among the under-recognised aetiologies. A small study that included patients with COPD or asthma not only detected that VCD was more common in patients with COPD than with asthma, but also that the frequency of VCD was higher in individuals with (very) severe COPD than in the mild/moderate setting [7]. Furthermore, Prof. Bhatt stated, “Another underappreciated source of dyspnoea in individuals with COPD is that of central airway collapse; it is associated with a high risk of moderate as well as severe exacerbations, but whether this is an indicator of risk or it is causal, is not clear at this time.” Prof. Bhatt concluded that even though all these aetiologies are biologically plausible, more data is needed to confirm them.
- Bhatt SP. Under Recognized Etiologies of Exacerbations. Session B027: Phenotyping acute exacerbations of COPD. ATS 2021 International Conference, 14-19 May.
- Bafadhel M, et al. Am J Respir Crit Care Med. 2011;184(6):662-71.
- Chen W, et al. Lancet Respir Med. 2015;3(8):631-9.
- Laurin C, et al. Am J Respir Crit Care Med. 2012;185(9):918-23.
- Iyer AS, et al. Ann Am Thorac Soc. 2016;13(2):197-203.
- Huang C, et al. BMC Pulm Med. 2020;20(1):2.
- Ruane L, et al. European Respiratory Journal 2019 54 (suppl. 63) OA272.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Does COPD plus COVID-19 equal higher mortality? Next Article
Metabolic dysfunction and lung disease: children are no small adults »
« Does COPD plus COVID-19 equal higher mortality? Next Article
Metabolic dysfunction and lung disease: children are no small adults »
Table of Contents: ATS 2021
Featured articles
Letter from the Editor
COVID-19: What Pulmonologists Need to Know
Antibody treatment for COVID-19: a combination is successful
Air pollution: an underestimated negative prognostic factor for COVID-19
Healthcare workers vulnerable to SARS-CoV-2 infections
Genetic risk variants responsible for COVID-19 predisposition
Asthma – An Update
“As-needed” inhaled corticosteroid therapy for mild asthma – what is the evidence?
IL-4/13 blocker successful in treatment of paediatric moderate-to-severe asthma
Benralizumab lives up to its phase 3 results in real-world findings
Tezepelumab – good success rates in various types of severe asthma
Sleep Disorders – An Underestimated Problem
OSA: A risk factor for earlier cognitive decline
Subgroup of patients with high heart rate response and coronary artery disease benefit from CPAP
Association between positive airway pressure treatment adherence and COVID-19 infection rates
COPD – What Is New
Possible aetiologies for COPD exacerbations – more evidence is needed
Does COPD plus COVID-19 equal higher mortality?
Biomarkers for acute exacerbations in COPD are required
Severe exacerbations: A key driver of all-cause mortality in COPD patients
Men and women with COPD differ in many ways
Younger adults with COPD at higher health risk than previously thought
Metabolic Dysregulation and Lung Disease
Obesity: A risk factor for new-onset asthma and worse asthma control
Metabolic dysfunction and lung disease: children are no small adults
Best of the Posters
Air pollution in winter linked to more hospital admissions in ILD patients
Tobacco biomarkers do not improve prediction of lung cancer risk
Vaping identified as risk factor for asthma
Related Articles
July 18, 2022
Novel PDE4B inhibitor offers breakthrough for IPF
August 17, 2022
Update on treatment of fibrotic ILD
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com